Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stannous Fluoride Dentifrice for Dentinal Hypersensitivity
NCT01592851Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2012
- Primary completion
- May 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of stannous fluoride in dentin hypersensitivity (DH) (2 arms), sponsored by GSK. Primary endpoint: Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Day 14. Started Apr 2012; status: completed.
02
Drugs
stannous fluoride
03
Conditions
dentin hypersensitivity (DH)
Beyond the preview
Go deeper on NCT01592851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01592851.